Searchable abstracts of presentations at key conferences in endocrinology

ea0063p1196 | Thyroid 3 | ECE2019

Stressful life events induce graves’ disease: further evidence for the role of stress as an inducing factor in graves’ disease

Kostoglou-Athanassiou Ifigenia , Athanassiou Lambros , Xanthakou Eleni , Spyropoulos Panagiotis , Kalogirou Thomais , Potamousi Paraskevi , Athanassiou Panagiotis

Introduction: Stress is a known risk factor for the development of Graves’ disease. We have previously described the role of bereavement as an inducing factor for Graves’ disease. Bereavement as an inducing factor for Graves’ disease was shown to affect primarily female patients after the loss of a loved one. However, it appears that other stressful life events may also cause Graves’ disease.Aim: The aim of the study was to describe t...

ea0070ep65 | Bone and Calcium | ECE2020

Differential clinical expression of primary hyperparathyroidism due to a parathyroid adenoma or hyperplasia

Kostoglou-Athanassiou Ifigenia , Athanassiou Lambros , Ginis Alexandros , Fortis Athanasios , Kalogirou Thomais , Athanassiou Panagiotis

Introduction: Primary hyperparathyroidism is nowadays frequently diagnosed due to routine blood calcium measured in the general biochemical profile. Primary hyperparathyroidism may be due to a parathyroid adenoma or parathyroid hyperplasia. Parathyroid adenoma may occur in the area of the parathyroid glands or may be ectopic.Aim: The aim was to describe the differential clinical expression of primary hyperparathyroidism due to an adenoma or hyperplasia i...

ea0070ep419 | Thyroid | ECE2020

Subclinical hyperthyroidism as a cause of atrial fibrillation

Athanassiou Lambros , Siarkos Evangelos , Fortis Athanasios , Kalogirou Thomais , Athanassiou Panagiotis , Kostoglou-Athanassiou Ifigenia

Introduction: Subclinical hyperthyroidism is a syndrome with vague clinical symptoms. It may cause tachycardia, loss of weight or no symptoms at all. Subclinical hyperthyroidism may occur in middle age and in the elderly. It may be related to the occurrence of atrial fibrillation. Subclinical hyperthyroidism may be the result of an autonomous goiter, may occur in the course of follow-up of hypothyroidism, as the needs for treatment may vary over time and substantially diminish...

ea0056ep150 | Reproductive Endocrinology | ECE2018

Amenorrhea and benign intracranial hypertension as an effect of antipsychotic therapy in a patient with schizophrenia

Kostoglou-Athanassiou Ifigenia , Athanassiou Lambros , Fortis Athanasios , Myriokefalitakis Ioannis , Kalogirou Thomais

Introduction: The management of schizophrenia involves drugs which inhibit domapine receptors. The drugs control the disease. However, they increase prolactin secretion and induce amenorrhea. The drugs induce the development of metabolic syndrome and as a result of obesity they may cause benign intracranial hypertension.Aim: The aim was to describe the case of a patient who developed schizophrenia and after therapy with antipsychotics benign intracranial...

ea0073aep68 | Adrenal and Cardiovascular Endocrinology | ECE2021

Primary hyperaldosteronism. A clinical profile of the disease without arterial hypertension

Kostoglou-Athanassiou Ifigenia , Athanassiou Lambros , Spyropoulos Panagiotis , Xanthakou Eleni , Fortis Athanasios , Kalogirou Thomais , Athanassiou Panagiotis

Primary hyperaldosteronism may be due to an adrenal adenoma and is an increasingly recognized cause of secondary arterial hypertension. The disease causes hypokalemia and is usually treated surgically by excision of the adrenal adenoma. However, it appears that it may present with a clinical profile without arterial hypertension. The aim was to describe three cases of primary hyperaldosteronism who presented with hypokalemia and an adrenal adenoma with normal blood pressure. A...

ea0073aep121 | Calcium and Bone | ECE2021

The endocrine effects of lithium treatment. Report of a case

Ifigenia-Kostoglou Athanassiou , Giannopoulos Georgios , Athanassiou Lambros , Nomikos Alexandros , Fortis Athanasios , Kalogirou Thomais

Lithium is considered a mainstay treatment option for the management of bipolar affective disorder. However, lithium administration is characterized by endocrine effects. The aim was to present the case of a patient who was on treatment with lithium for many years for the management of bipolar affective disorder and presented with a large parathyroid adenoma causing clinical hyperparathyroidism with severe hypercalcemia who was successfully treated by surgical excision of the ...

ea0014p89 | (1) | ECE2007

Lipoprotein Lp(a) in patients with systemic lupus erythematosus. Relationship with disease activity and anticardiolipin antibodies

Athanassiou Panagiotis , Kostoglou-Athanassiou Ifigenia , Papadopoulou Despina , Galanaki Chrysoula , Kalogirou Thomais , Kordalis Athanasios , Antoniadis Christodoulos , Kaldrymidis Philippos

Systemic lupus erythematosus (SLE) is a multisystem multifactorial autoimmune disorder. The survival of SLE patients has been improved by the administration of immunomodulatory therapy. Patients, however, are affected by late onset complications of the disease such as atherosclerosis. Lipoprotein Lp(a) is a known risk factor for the development of atherosclerosis.The aim was to study Lp(a) levels and their relationship with disease activity in SLE patien...

ea0014p90 | (1) | ECE2007

Lipoprotein Lp(a) in patients with rheumatoid arthritis and its relationship with disease activity

Athanassiou Panagiotis , Kostoglou-Athanassiou Ifigenia , Papadopoulou Despina , Galanaki Chrysoula , Kalogirou Thomais , Kordalis Athanasios , Antoniadis Christodoulos , Kaldrymidis Philippos

Epidemiological studies indicate that rheumatoid arthritis (RA) patients have increased mortality. Cardiovascular disease seems to be one of the major causes of death in patients with RA. Lipoprotein disorders are observed in patients with systemic autoimmune disorders as well as in patients with RA. Lipoprotein Lp(a) is an independent risk factor for the development of cardiovascular disease.The aim of the study was estimate lipoprotein Lp(a) levels and...

ea0073aep130 | Calcium and Bone | ECE2021

The benign course of MEN I disease. Implications for treatment

Athanassiou Lambros , Kostoglou-Athanassiou Ifigenia , Spyropoulos Panagiotis , Xanthakou Eleni , Mascha Olga , Fortis Athanasios , Kalogirou Thomais , Athanassiou Panagiotis

MEN (multiple endocrine neoplasia) I disease represents a compilation of multiple endocrine neoplasms affecting a patient in the course of a life-time. It thus represents a phenotype which has survived over many years. Pituitary neoplasms, lipomas and parathyroid hyperplasia are observed in the disease. The aim was to describe a patient with MEN I disease who presented with lipomas and acromegaly in his early adulthood and developed primary hyperparathyroidism in his senior ye...